iBio updates corporate presentation highlighting obesity and cardiometabolic disease antibodies

iBio, Inc.

Filed updated corporate presentation dated June 2025 for investor meetings.
Presentation focuses on breakthrough antibodies for obesity and cardiometabolic diseases.
No financial or pipeline specifics disclosed in the filing or attached exhibit.

item 7.01 item 8.01 item 9.01

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001420720-25-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.